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Mental diseases are rising globally. Depression is one among the most common mental disorders with an alarmingly high 
incidence in India. Mental health care in general is suboptimal in India on account of inadequate resources and lack of 
awareness. Pluralistic health care delivery model of India including its traditional health care services is less explored in 
case of mental health for its possibility of adding value to the net mental health care delivery. The objective of the study was 
to explore the efficacy of an ayurvedic formulation Lasunadya Ghrita (LG) in a multimodal application form in cases of 
depression and to compare its efficacy with conventional care composed of Escitalopram, Etizolam and Zolpidem (EEZ) 
provided in an allopathic psychiatric health care setting. Total 52 patients of depression allocated non randomly to Ayurveda 
LG group and to Allopathy EEZ group were followed up for 4 weeks and evaluated on the basis of HAM-D and SF-36 mean 
score changes of the participants on a pre and post basis and also for their intergroup comparisons. Statistically significant 
changes in mean HAM-D and SF-36 Score were observed in a pre-post comparison in both the groups. An intergroup 
comparison was non- significant for majority of HAM-D domains, barring a few showing the comparable effects of two 
treatment approaches. Ayurvedic treatment was effective in work and energy domain and gastrointestinal symptoms. 
Pre and post mean changes in HAM-D and SF-36 Score in two groups have shown significant changes in both the groups 
suggestive of their individual efficacy. Insignificant difference in most domain scores of HAM-D and SF-36 in an inter 
group comparison was suggestive of comparable efficacy of LG multi route application with EEZ allopathy care.   
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Mental diseases are the cause of a global concern for 
their impact upon more than 1 billion people globally. 
Estimated global burden of mental disorders accounts 
for 32.4% of all years lived with disability (YLD) and 
13% of disability adjusted life years (DALY)1. These 
figures place mental illness very high in global burden 
of diseases in terms of years lived with disease (YLD) 
and at par with cardiovascular diseases in terms of 
DALY. 
Despite their high burden, unfortunately mental 
healthcare in general is found disproportionate, 
inequitable, inaccessible and inadequate across the 
world with more pronounced impacts upon lower and 
middle income countries including India2,3. Recent 
estimates suggest India having 150 million people 
suffering with some kind of mental illness with a 
meager strength of ~4000 psychiatrists to deal with 
this burgeoning burden of mental diseases4.  
Mental diseases in contrast to physical illnesses are 
unique for their ethno-cultural hues and ethos and 
hence also require a contextual management. From 
Indian perspective, owing to its diverse culture and 
pluralistic health care opportunities, utilizing 
traditional health care for mental diseases seems to be 
a plausible proposition5. Indian National mental 
health care policy 2017 was a right step in this 
direction for its identification of Ayurveda as an 
integral component of composite mental health care 
delivery in India6. 
Among all mental diseases, depression shares the 
maximum brunt of DALY. Depression is emerging as 
a global epidemic accounting for its huge implications 
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in various spheres of life including social, personal 
and economical7. Seeing the phenomenal increase of 
depression incidence and its impact on society, WHO 
took an initiative to start a dialogue for depression by 
assigning ‘Depression: let’s talk’ as a theme for  
year 20178.  
Depression as a disease has many peculiarities. 
Having an early incidence, it may arise through life 
style, workplace or family issues and may result in 
huge personal, interpersonal, social and economic 
losses including lives lost due to suicide9. India 
currently has about 5.6 crore people amounting to 
4.5% of its population suffering with depression10. 
The prevalence of depression is increased by 18% 
worldwide in past 10 years and is projected to rise 
further in next 10 years11. With this alarming hike in 
depression incidence, an urgent recount of our 
strength for meeting the emerging demands of mental 
health care is direly needed.  
Pharmacotherapy of depression care has not been 
very promising so far12. It has limitations related to 
delayed onset of action, side effects, dependency and 
longer treatment requirements. Clinical trials related 
to depression have continuously failed to distinctly 
differentiate the effects of placebo and active 
interventions. Depression is still a stigma in India. 
Because of the ignorance about psychiatric illnesses 
and overriding preoccupations to the axiom that 
"psychiatrists are the doctors of mad people" visiting 
a psychiatrist is still a taboo in most parts of the 
country13. 
For its ethno cultural rooting in India, in mental 
health care, Ayurveda emerges as a serious player to 
bridge the gaps. For its cultural contextuality, 
Ayurveda has a higher acceptability in the area of 
mental health care. The benefits of appropriating 
Ayurveda for optimizing mental health in India can be 
many, most immediate of which is easing out the 
disease burden by sharing the care with existing 
facilities and by providing more accessible care to a 
larger niche area. Looking optimistic however, this 
proposition requires a robust scientific exploration to 
move further. The first step here could be the 
screening of Ayurvedic interventions for their 
therapeutic potentials in depression14.  
It is in this intriguing background of high burden of 
depression in India along with its suboptimal care, 
potential of Ayurvedic medicine to handle such 
conditions deem highly desired. This study aimed to 
explore the role of an ayurvedic formulation 
Lasunadya Ghrita (LG) used in a multi route mode 
(oral and nasal instillation) in cases of primary 
depression through a non random open label clinical 
trial. It has compared the benefits of LG to 
conventional care of primary depression composed of 
Escitalopram, Etizolam and Zolpidem (EEZ)15. One 
recently published review article has suggested the 
connections between gut dysregulation and major 
depressive disorders, and points out the importance of 
gut health in restoration of mental functions16. The 
intervention drug from Ayurveda selected for the trial 
has a high affinity for re-correction of gut 
dysregulation and hence seems appropriate for this 
clinical trial.  
Done upon 52 patients (26 participants in each 
group) allocated in a non random way, the study was 
able to demonstrate the benefits of LG multi route 
applications comparable to conventional EEZ care 
(comprised of Escitalopram 10 mg , Etizolam 0.25 
mg, and Zolpidem 10 mg every day in single dose). 
On clinical domains related to work-activity-energy, 
early and middle insomnia and somatic symptoms 
pertaining to gastrointestinal functions, effects of LG 
were found superior to EEZ. The observations made 
in the study are serious enough to consider Ayurveda 
as a plausible partner in a comprehensive and holistic 
management plan for depression.  
 
Materials and Methods  
 
Setting of the study 
The study was conducted at State Ayurvedic 
College and Hospital, Lucknow in collaboration with 
the Department of Psychiatry, King George’s Medical 
University, Lucknow. Patients were recruited from 
both the places and were given the treatment as per 
the place of their recruitment.  
 
Necessary permissions and ethical clearance 
Necessary permissions and ethical clearance were 
duly obtained from the Institutional Ethics Committee 
(IEC/AYM/066-2017 Dt.25.08.2018). The study was 
also registered with Clinical Trial Registry of India 
(CTRI2019/08/020756). All the participants in the 
study have been informed well about the study and an 
informed consent was obtained following the due 
process. 
 
Study design  
This was a non random two arm open label study 
where one arm (Group A) of the study was given LG 




(through oral and nasal route) and the other arm 
(Group B) was given EEZ for one month. This period 
was selected on the assumption that for any anti-
depressant drug to act, it takes around 4 weeks to give 
the observable results.   
 
Study sample and participants recruitment 
Depression patients diagnosed on the basis of 
WHO-ICD 10, DCR criteria for mild to moderate 
depression17 and fulfilling the essential inclusion and 
exclusion criteria were recruited from State 
Ayurvedic College, Lucknow (place of recruitment 
for group A patients) and Department of Psychiatry, 
King George Medical University, Lucknow (Place of 
recruitment for group B patients), respectively. 
Informed consent was obtained from prospectively 
suitable participants and those willing to participate 
were allocated the group as per their primary 
recruitment place (This was a non random study and 
the patients were enrolled from ayurvedic and 
allopathic hospital, respectively and given the 
treatment as per the specific hospitals). Patients 
having other psychiatric co-morbidities and severe 
depression with attempted suicides have been 
excluded from the study.  
 
Sample size  
Considering the 5% margin of error and 95% 
confidence interval and 4.5% disease prevalence, the 
study sample was determined to be 385. However, 
considering the pilot nature of study, the study sample 
was limited to 60 with a proportionate distribution of 1:1 
in two groups. Considering 20% drop outs, total sample 
is 72 with approximate 36 participants in each group.  
 
Trial drug and active comparator 
Lasunadya Ghrita (LG) originally cited in Charak 
Samhita for the treatment of Unmada (a psychiatric 
condition described in Ayurveda resembling with 
mood disorders) was selected as the trial drug on the 
basis of its textual praise in depression like 
symptoms18. The drug was prepared at a local GMP 
certified ayurvedic pharmacy and was packed in the 
dose form suitable for oral consumption for 28 days. 
It was given orally in 2.5 g dose two times every day 
before meal for 4 weeks. For nasal instillation 
(nasya), 6 drops (~0.3 mL) of the drug were instilled 
in each nostril following strict SOP of nasya as 
recommended in Ayurveda. Nasal instillation on each 
patient each time was done by the investigator (VT) 
herself in the hospital setting in the morning hours. 
Total 20 nasal instillations dispersed in 4 weeks were 
given to each patient in Group A (approximately 5 
sittings in a week). The Group B patients were given 
Escitalopram 10 mg, Etizolam 0.25 mg, and Zolpidem 
10 mg once in a day for 4 weeks. These drugs were 
purchased by the patients from the local market. For 
the oral drug intake compliance in both the groups, a 
compliance diary was recommended to be made by 
every registered patient and was checked from time to 
time by the investigator (VT).  
 
Conduction of the study  
The study has begun in April 2018 and completed in 
July 2019. Total 68 patients of depression (38 from 
group A i.e., recruited from ayurvedic hospital and  
30 from group B i.e., recruited from allopathic hospital) 
were screened for their eligibility in the study and 
subsequently asked for their willingness to participate in 
the study through an informed consent process. Total 32 
eligible patients in Group A and 30 in Group B have 
given their consent to participate in the study. The data 
was finally analyzed on 52 patients, comprising of 26 
patients in each group. Data pertaining to 10 patients 
was incomplete due to the lost follow ups and therefore 
was not included in the final analysis (study flow chart).  
 
Evaluation parameters  
Primary evaluation of the changes in the clinical 
status of depression following the active Ayurveda 
treatment or the Allopathic care was done on the basis 
of mean changes in the HAM-D score19. A secondary 
outcome was also evaluated through finding the 
changes in mean SF-36 scores20 in both the groups. 
The groups were initially compared at their base line 
to see the similarity of their demographic and clinical 
profiles. Subsequently, a pre and post comparison was 
done to see any statistically valid difference between 
the HAM-D baseline and 4 week scores obtained after 
the treatment in each group. An intergroup 
comparison was also done for HAM-D and SF-36 
mean score changes obtained in two groups at various 
time intervals. Safety of the interventions was also 
evaluated through pre and post liver and kidney 
function tests and lipid profile in both the groups.  
 
Results  
The final evaluation was done on 52 patients 
comprising of 26 participants in each group. Mean 
age of the patients registered and finally analyzed in 
the study was 36 years with a mean of 38.38 year in 
Group A and 33.7 years in group B (Inter group 




x2=1.622 and p=0.805). Maximum number of patients 
in both the groups was 20-39 years of age. A male 
predominance was observed among the registered 
participants. A high literacy level was obtained in 
both the groups under study (100% in group A, 92% 
in group B). The study has shown the marital conflicts 
as an important predisposing factor for depression. 
Financial issues also emerged as a large precipitant to 
depression in the study. 
HAM-D and SF-36 were important evaluation 
parameters utilized in this study. These parameters were 
statistically evaluated for any difference in their scores 
in two groups at the time of registration, during the 
follow-up and on completion of the study. No significant 
differences were elicitable in baseline total HAM-D and 
SF 36 scores in two groups showing the comparability 
of two groups. Out of 21 domains scores enquired in 
HAM-D, 16 were found statistically indifferent in group 
A and B at the time of registration. Significant 
differences however were observed in Group A and 
Group B in domains like Insomnia (early, middle and 
late), Anxiety (psychological) and Hypochondrias is at 
the time of registration showing their different intensities 
in two groups before the start of therapy.  
 
Pre and post treatment comparison  
In group A significant difference was found in 
mean HAM-D score from Day 0 to Week 4 (46.29%, 
p<0.001). Similar difference in mean HAM-D score 
was also observed in group B from Day 0 to  
Week 4 (61.66%, p<0.001). (Table 1). 
 
Pre and post treatment comparison of individual domain 
scores in HAM-D 
A pre and post treatment comparison was further 
done for all the domains of HAM-D to see if there are 
any domain specific differences in responses of the 
two groups (Table 2). This has shown that after 4 
weeks of the treatment, in group A, significant 
Table 1 — Pre and post treatment changes in HAM-D Score in Group A and Group B 





















Day 0-Week 2  2.77 1.31 12.72 -4.48 <0.001 7.08 2.46 28.22 -4.47 <0.001 
Day 0-Week4 10.08 2.17 46.29 -4.47 <0.001 15.46 3.84 61.66 -4.46 <0.001 
 
Table 2 — Pre and post treatment comparison of HAM-D domain scores between Day 0 and 4th week in Group A and B 
Domain Group A Group B 
% Improvement z-value p-value  % Improvement z-value p-value 
Depressed mood 79.37 -4.59 <.001 69.70 -4.65 <.001 
Feeling of Guilt 2.63 -1.00 .317 48.65 -2.97 .003 
Suicide 50.00 -2.46 .014 27.78 -2.24 .025 
Insomnia Early 41.18 -3.30 .001 89.13 -4.54 <.001 
Insomnia Middle 53.33 -2.83 .005 93.94 -4.24 <.001 
Insomnia Late 62.96 0.00 1.000 93.18 -4.46 <.001 
Work & Activities 65.79 -4.62 <.001 56.79 -4.72 <.001 
Psychomotor Retardation 84.62 -3.32 .001 72.73 -2.53 .011 
Agitation 22.22 -2.12 .034 60.61 -3.54 <.001 
Anxiety (Psychological ) 65.00 -4.06 <.001 59.68 -4.40 <.001 
Anxiety (Somatic) 54.76 -4.07 <.001 52.08 -4.63 <.001 
Somatic Symptoms 
(Gastrointestinal) 
90.32 -4.18 <.001 41.38 -3.46 <.001 
Somatic Symptoms (General 50.00 -4.30 <.001 64.10 -4.46 <.001 
Genital Symptoms 0.00 0.00 1.000 23.81 -2.24 .025 
Hypochondriasis 5.56 -1.00 .317 33.33 -1.41 .157 
Loss of Weight 9.52 -1.00 .317 5.26 -0.27 .785 
Insight 0.00 0.00 1.000 100.00 -1.00 .317 
Diurnal Variation 21.74 -1.89 .059 95.00 -3.07 .002 
Depersonalization & 
Derealization 
25.00 -1.00 .317 0.00 0.00 1.000 
Paranoid Symptoms 0.00 0.00 1.000 0.00 0.00 1.000 
Obsessional & Compulsive 
Symptoms 
0.00 0.00 1.000 21.43 -1.73 .083 




improvements were seen in the domains like 
depressed mood, suicide, insomnia early, insomnia 
middle, work & activities, psychomotor retardation, 
agitation, anxiety (psychological), anxiety (somatic), 
somatic symptoms (gastrointestinal) and somatic 
symptoms (general). In Group B, after 4 weeks, 
significant improvements were found in all the 
domains except hypochondriasis, loss of weight, 
insight, depersonalization & de-realization, paranoid 
symptoms and obsessive and compulsive symptoms. 
 
Pre and post treatment comparison of changes in SF-36 score 
in two groups  
In group A significant difference in mean SF-36 
score was found from Day 0 to Week 4 (44.19%, 
p<0.001). Similar difference was also observed in 
Group B in mean SF -36 score from Day 0 to 4th week 
(59.29%, p<0.001) (Table 3).  
 
Intergroup comparison of changes in HAM-D score in two 
groups 
No significant intergroup difference was observed 
at Day 0, 2nd week and 4th week mean HAM-D scores 
obtained in two groups.  
On comparing the difference in HAM-D mean 
score between Day 0 and 4th week, the mean HAM-D 
score difference of group A was 10.08±2.17, whereas 
the mean HAM-D score difference of group B was 
15.46±3.84. This intergroup difference in mean 
change of HAM-D score from day 0 to week 4 was 
significantly different (p<0.001), favoring more 
reduction in mean HAM-D score in Group B 
comparing to group A (Table 4). 
 
Intergroup comparison of changes in SF-36 score in two 
groups 
No significant differences in mean SF-36 score at 
Day 0, 2nd week and 4th week was observed in an 
intergroup comparison of Group A and B. On 
comparing the difference in SF-36 score between Day 
0 and 4th week, the mean SF-36 score difference of 
group A was found to be 515.38±143.19, whereas the 
mean SF-36 score difference of group B was 
604.23±133.94. No significant difference was found 
in mean SF-36 scores changes from day 0 to week 4 
in two groups (p=0.117) (Table 5). 
 
Intergroup comparison of changes in domain scores in  
HAM-D 
After 4 weeks, significant differences between the 
groups were found for the domains like feeling of 
guilt (p=0.010), insomnia early (p=0.001), insomnia 
late (p<0.001), work & activities (p=0.020), anxiety 
(psychological) (p=0.007), somatic symptoms 
(gastrointestinal) (p<0.001), somatic symptoms 
(general) (p=0.017), hypochondrias is (p=0.012) and 
diurnal variation (p=0.001) (Table 6).  
More pronounced intergroup differences favoring 
Group A were found in domains like work & 
activities (p=0.020) and somatic symptoms 
(gastrointestinal) (p<0.001), 
Intergroup differences favoring Group B were 
found in domains like feeling of guilt (p=0.010), 
insomnia early (p=0.001), insomnia late (p<0.001), 
anxiety (psychological) (p=0.007), somatic 
Table 3 — Pre and post treatment changes in SF-36 Score in Group A and Group B 





















Day 0-Week 2  -135.00 77.97 11.57 -4.46 <0.001 -262.31 62.15 25.74 -4.46 <0.001 
Day 0-Week4 -515.38 143.19 44.19 -4.46 <0.001 -604.23 133.94 59.29 -4.46 <0.001 
 
Table 4 — Intergroup Comparison of HAM-D Scores between the Groups 
HAMD Score Group A Group B Mann Whitney Test 
Mean SD  Mean SD  U-value p-value 
Day 0 21.77 ±5.87 25.08 ±4.63 231.0 0.050 
2nd Week 19.00 ±5.51 18.00 ±3.45 291.5 0.393 
4th Week 11.69 ±4.43 9.62 ±2.28 246.0 0.090 
Diff Day 0 to 4th Week 10.08 ±2.17 15.46 ±3.84 23.3 <0.001 
Table 5 — Intergroup Comparison of SF-36 QL Scores  
between the Groups 
SF-36 Score Group A Group B Mann Whitney Test
Mean SD Mean SD U-value p-value 
Day 0 1166.35 ±256.67 1019.04 ±170.89 232.0 0.052 
2nd Week 1301.35 ±240.27 1281.35 ±150.81 336.0 0.971 
4th Week 1681.73 ±186.79 1623.27 ±131.54 262.5 0.167 
Diff Day 0 to  
4th Week 
515.38 ±143.19 604.23 ±133.94 2.5 0.117 




symptoms (general) (p=0.017), hypochondriasis 
(p=0.012), and diurnal variation (p=0.001).  
 
Safety, adversity and toxicity observations  
No drug related adversity has been reported during 
the study period in either group. No significant 
differences were observed in their pre and post 
treatment values in any biochemical or hematological 
parameters including Liver function, Kidney function 
and lipid profile in either of the groups.  





Depression for its huge impacts upon individual 
and societal health and for its increasing global 
incidence, requires an urgent attention. A limitation of 
current therapeutic approaches linked to the resource 
deficit or intervention related undesired effects, 
Table 6 — Intergroup Comparison of Depression Domain Scores between the Groups 
Domains  Time period Group A Group B Mann Whitney Test 
Mean SD Mean SD U-value p-value 
Depressed mood Day 0 2.42 0.90 2.54 0.71 303.5 0.494 
4th Week 0.50 0.65 0.77 0.51 247.5 0.061 
Feeling of Guilt Day 0 1.46 0.90 1.42 0.90 334.5 0.939 
4th Week 1.42 0.86 0.73 0.96 213.0 0.010 
Suicide Day 0 0.69 0.97 0.69 0.55 294.0 0.369 
4th Week 0.35 0.56 0.50 0.51 279.5 0.211 
Insomnia Early Day 0 1.31 0.79 1.77 0.51 228.0 0.017 
4th Week 0.77 0.71 0.19 0.40 185.0 0.001 
Insomnia Middle Day 0 0.58 0.58 1.27 0.67 162.5 <.001 
4th Week 0.27 0.45 0.08 0.27 273.0 0.070 
Insomnia Late Day 0 1.04 1.00 1.69 0.74 223.0 0.010 
4th Week 1.69 4.05 0.12 0.33 178.5 <.001 
Work & Activities Day 0 2.92 0.80 3.12 0.91 288.5 0.296 
4th Week 1.00 0.63 1.35 0.56 231.5 0.020 
Psychomotor  
Retardation 
Day 0 0.50 0.71 0.42 0.76 305.5 0.482 
4th Week 0.08 0.39 0.12 0.33 313.5 0.332 
Agitation Day 0 1.04 1.11 1.27 1.00 286.0 0.312 
4th Week 0.81 1.02 0.50 0.51 299.0 0.426 
Anxiety  
(PSYCHOLOGICAL) 
Day 0 1.54 0.95 2.38 0.85 157.5 <.001 
4th Week 0.54 0.51 0.96 0.53 213.0 0.007 
Anxiety  
(SOMATIC) 
Day 0 1.62 0.80 1.85 0.67 290.0 0.260 
4th Week 0.73 0.45 0.88 0.33 286.0 0.163 
Somatic Symptoms 
(GASTROINTESTINAL) 
Day 0 1.19 0.75 1.12 0.77 319.5 0.716 
4th Week 0.12 0.33 0.65 0.49 156.0 <.001 
Somatic Symptoms  
(GENERAL) 
Day 0 1.69 0.55 1.50 0.65 284.5 0.241 
4th Week 0.85 0.37 0.54 0.51 234.0 0.017 
Genital Symptoms Day 0 0.77 0.91 0.81 0.80 322.0 0.753 
4th Week 0.77 0.91 0.62 0.70 318.0 0.689 
Hypochondriasis Day 0 0.69 0.97 0.23 0.82 243.0 0.018 
4th Week 0.65 0.94 0.15 0.54 237.0 0.012 
Loss of Weight Day 0 0.81 1.13 0.73 0.83 330.0 0.871 
4th Week 0.73 1.12 0.69 0.84 323.0 0.756 
Insight Day 0 0.08 0.39 0.08 0.39 338.0 1.000 
4th Week 0.08 0.39 0.00 0.00 325.0 0.317 
Diurnal Variation Day 0 0.88 0.91 0.77 0.91 314.0 0.631 
4th Week 0.69 0.88 0.04 0.20 204.5 0.001 
Depersonalization  
& Derealization 
Day 0 0.15 0.46 0.04 0.20 311.5 0.294 
4th Week 0.12 0.33 0.04 0.20 312.0 0.303 
Paranoid Symptoms Day 0 0.12 0.33 0.08 0.27 311.0 0.609 
4th Week 0.12 0.33 0.08 0.27 311.0 0.609 
Obsessional  
& Compulsive Symptoms 
Day 0 0.28 0.61 0.54 0.58 238.0 0.051 
4th Week 0.28 0.61 0.42 0.50 263.5 0.153 




warrants a search for better alternatives. India having 
a pluralistic health care model has many alternative 
health care systems including Ayurveda to help in 
psychiatric diseases due to their strong cultural and 
social bearing21. 
Reverse pharmacology has been a tested approach 
to develop new solutions for old problems on the 
basis of clues obtained from available traditional 
references for natural remedies22. LG was screened as 
a potential drug for depression on the basis of its 
description available in Charaka Samhita (CS), a 
classical treatise of Ayurveda presumed to be of 200 
BC. This drug is composed of rasona (Allium 
sativum) as one of its main ingredients besides many 
other herbal components having ushna (hot) tikshana 
(pungent) and srotoshodhana (passage cleansing) 
properties (Table 9). An ayurvedic hypothesis 
developed to propose the possible mechanism of LG 
in depression largely favoured its postulated actions in 
depression. The classical recommendation of LG in 
CS was to use it through oral and nasal routes and 
also through external massage. Nasal route of drug 
Table 7 — Effect of Treatment on biochemical and hematological parameters in Group A 
Laboratory Parameter Time Group A 
Mean SD % change t-value p-value 
Hemoglobin (g%) BT 13.23 1.45    
AT 13.04 1.59 1.42 1.13 0.269 
Total Leucocyte Count BT 7692.31 1081.45    
AT 7692.31 1043.43 0.00 0.00 1.000 
Neutrophil BT 59.19 5.59    
AT 59.04 5.50 0.26 0.55 0.589 
Lymphocyte BT 30.81 5.18    
AT 31.73 6.29 3.00 1.58 0.184 
Monocyte BT 4.81 3.29    
AT 5.31 4.36 10.40 1.98 0.056 
Eosinophil BT 2.65 1.38    
AT 2.73 1.25 2.90 -0.46 0.646 
Basophil  BT 1.19 1.27    
AT 1.00 1.02 16.13 1.73 0.096 
TOTAL CHOLESTEROL (mg/dL) BT 174.73 12.67    
AT 175.04 12.61 0.18 -0.82 0.420 
L.D.L. (mg/dL) BT 101.77 18.14    
AT 101.46 18.12 0.30 0.94 0.356 
VLDL (mg/dL) BT 28.65 4.57    
AT 29.19 4.89 1.88 1.29 0.246 
HDL (mg/dL) BT 43.42 2.79    
AT 43.73 3.01 0.71 -1.14 0.266 
T.G. (mg/dL) BT 149.69 11.86    
AT 150.00 11.85 0.21 -0.89 0.381 
S. BILIRUBIN (mg/dL) BT 0.54 0.23    
AT 0.55 0.21 1.92 -1.34 0.193 
 ALKALINE PHOSPHATASE (IU/L) BT 96.73 11.41    
AT 97.15 11.20 0.44 -0.90 0.375 
SGOT (Units per liter) BT 27.85 8.99    
AT 27.88 9.13 0.14 -0.13 0.898 
SGPT (Units per liter) BT 30.46 9.15    
AT 30.65 9.80 0.63 -0.38 0.705 
B. UREA (mg/dL) BT 29.04 3.03    
AT 29.46 2.89 1.46 -1.74 0.094 
S. CREATININE (mg/dL) BT 0.89 0.20    
AT 0.90 0.20 1.17 -0.50 0.624 




application is highly acclaimed in Ayurveda for 
diseases pertaining to the head. Recent researches 
have supported this opinion of Ayurveda by finding 
that the drugs given through nasal routes may bypass 
the blood brain barrier and hence may directly reach 
to the brain tissue and therefore may assure a site 
specific delivery23. This novel drug routing, yet is less 
explored in conventional psychiatric care24. This 
study utilizing a multi route application including 
both oral and nasal routes simultaneously in a 
presumption to maximize the impact of the drug was 
also a validity test for Ayurvedic recommendation  
of nasal route of drug application for mental  
diseases.  
Testing the Ayurvedic drug efficacy for depression 
against the conventionally used pharmacotherapy was 
a most feasible plan to check if the drug in question 
has a comparable efficacy. An intergroup comparison 
of initial HAM-D and SF-36 QL scores assured no 
significant statistical differences and hence endorsed 
the similarity of the samples registered in both  
the groups. 
Table 8 — Effect of Treatment on biochemical and hematological parameters in Group B 
Laboratory Parameter Time Group B 
Mean SD % change t-value p-value 
Haemoglobin (g %)  BT 12.65 1.60    
AT 12.69 1.76 0.30 -0.25 0.802 
Total Leucocyte Count BT 7165.38 662.08    
AT 7173.08 636.59 0.11 -0.32 0.753 
Neutrophil BT 58.77 9.70    
AT 59.15 9.88 0.65 -1.85 0.076 
Lymphocyte  BT 31.00 4.93    
AT 31.50 4.81 1.61 -1.73 0.097 
Monocyte  BT 2.96 1.37    
AT 3.35 1.52 12.99 -2.61 0.015 
Eosinophil  BT 1.27 1.31    
AT 1.46 1.17 15.15 -1.55 0.134 
Basophil BT 0.54 0.65    
AT 0.48 0.64 10.86 1.13 0.278 
TOTAL CHOLESTEROL (mg/dL) BT 173.96 9.32    
AT 174.08 9.13 0.07 -0.33 0.746 
L.D.L.( mg/dL) BT 82.42 8.86    
AT 83.00 9.08 0.70 -1.81 0.083 
VLDL (mg/dL) BT 31.69 2.71    
AT 32.08 2.64 1.21 -1.73 0.096 
HDL (mg/dL) BT 44.58 8.42    
AT 45.85 7.71 2.85 1.87 0.112 
T.G. (mg/dL) BT 144.19 10.36    
AT 145.54 17.49 0.93 1.94 0.068 
S. BILIRUBIN (mg/dl) BT 0.50 0.42    
AT 0.52 0.61 3.60 1.88 0.115 
ALKALINE PHOSPHATASE (IU/L) BT 101.00 9.13    
AT 101.46 9.13 0.46 -0.99 0.334 
SGOT(Units per liter) BT 29.81 2.73    
AT 29.96 2.75 0.52 -0.58 0.566 
SGPT (Units per liter) BT 32.08 4.46    
AT 32.62 5.68 1.68 1.65 0.111 
B. UREA (mg/dL) BT 31.15 2.96    
AT 31.54 2.75 1.23 -1.73 0.096 
S. CREATININE (mg/dL) BT 0.80 0.08    
AT 0.81 0.09 0.72 -0.53 0.597 




Responses of the treatments were observed in 
individual groups and were analyzed for their 
significance on the basis of mean changes in HAM-D 
and SF-36 QL scores before, during the follow-ups and 
after completion of the trial. After initial pre and post 
analysis, an intergroup comparison was also done to 
see any quantitative difference in the responses 
obtained in both the groups and to see if this difference 
refers to certain specific domains in HAM-D scale.  
This was observed that both groups were able to 
give statistically significant improvements in 4 
weeks of treatment period in terms of HAM-D mean 
score changes and SF 36 QL mean score changes. 
These changes were more pronounced for Group B 
(EAZ) comparing to Group A (LG) for HAM-D 
mean score change however no such significant 
intergroup difference was found for SF-36 mean 
score changes. This was a landmark observation 
showing that Ayurvedic trial intervention for 
depression as is provided to Group A participants 
has shown comparable results in terms of quality of 
life improvements when compared to standard 
modern care given to the Group B patients. This was 
substantiated further by seeing statistically 
significant differences in HAM-D mean score in 
Group A before and after 4 weeks of the treatment. 
The dichotomy of observations seen through two 
evaluation parameters also proposes different mode 
of action of two interventions used in the trial. A 
better HAM-D scoring through Group B intervention 
proposes the direct action of these drugs onto 
symptoms of depression. Group A drug (LG) 
however seem to act through different pathways by 
improving the quality of life initially and correcting 
the depression subsequently.  
A domain mean score analysis for HAM-D was 
also revealing by finding that the interventions given 
in group A and B had their differential responses to 
different domain specific variables of HAM-D. For 
domains like depressed mood, feeling of suicide, 
psychomotor retardation, somatic anxiety, genital 
symptoms, loss of weight, insight, depersonalization 
and de-realization, paranoid symptoms, obsessional 
and compulsive symptoms, the effects of the 
treatments were similar in both the groups after 4 
weeks of the treatment as is shown by insignificant 
difference between two groups in these domain areas 
after the completion of four week of treatment. This 
may thereby be inferred that in these domain areas of 
clinical features of depression, symptoms were as 
effectively cared for by Ayurvedic regime as is done 
by modern standard care. For few other symptoms 
there were differences in responses obtained between 
two groups and here the responses have favored the 
effect of one treatment over the other. For symptoms 
like feeling of guilt, late insomnia, psychological 
anxiety and general somatic symptoms, 
hypochondriasis and diurnal variation the modern 
standard care was found significantly more effective 
comparing to the given Ayurvedic intervention after 4 
weeks of therapy. For few other symptoms like work 
and activities and somatic symptoms pertaining to the 
gastrointestinal system Ayurvedic treatment was 
found more effective comparing to the standard 
modern care and this difference was shown by the 
significant statistical differences between the score 
obtained by the two groups after the completion of 4 
week of the therapy.  
These observations suggest about comparable 
efficacy of Ayurvedic interventions (LG) through its 
multi route application with modern standard 
interventions (EAZ) for depression when compared 
through changes in HAM-D and SF-36 scores. These 
effects however were distinct when compared in 
Table 9 — Ingredients of Lasunadya Ghrita 
No Ingredient name  English name  Latin name  Quantity/ proportion  
1 Lasun Garlic Alium sativum L. 100 part 
2 Haritaki Myrobillon  Terminalia chebula Retz. 30 part  
3 Shunthi Dried ginger Gingiber officinale Rosc.  1 part 
4 Marich Black pepper Piper nigrum L. 1 part 
5 Pippali  Long pepper Piper longum L. 1 part 
6 Go Dugdha Cow milk   64 part 
7 Purana Go Ghrita  Old Clarified butter   64 part 
8 Go mutra  Cow urine   16 part  
9 Hingu Asafoetida Ferula asafoetida L. 1 part  
10 Madhu Honey   8 part  




individual domain areas of HAM-D. This proposes 
that a selective treatment strategy for depression may 
be more productive if the selection is based on the 
predominating symptoms with evidences of one 
treatment doing better than the other. A depression 
patient having predominant symptoms related with 
late insomnia may better be treated with modern 
standard care whereas a depression patient having 
predominant somatic symptoms related to the work, 
energy and gastrointestinal symptoms may obtain a 
better response through Ayurvedic interventions. This 
observation may have a very significant future 
implication warranting the need of identifying clinical 
subgroups within a large population of depression 
where each group may have a different pathogenesis 
and therefore may need a different approach of 
treatment. There were no meaningful differences 
among pre and post treatment values of selected 
biochemical and hematological parameters to ensure 
safety and non toxicity of the drug. No significant 
changes in lipid profile in the patients treated with LG 
has eliminated the myth of alteration in the lipid 
levels by ayurvedic drugs composed of ghrita 
(Clarified butter).  
This study had its own limitations. It was a non 
random study which is considered inferior to a 
random study. Although, the group allocation was 
seen balanced in the study by finding no significant 
differences between the clinical profiles of the 
participants before the trial actually begun, a 
randomization may have given more strength to the 
study observations. The study was done for a short 
period only. For a disease like depression, a long 
term trial is required to evaluate the effects of a 
drug and also its safety. A long duration trial 
therefore is required to verify the observations 
made in this study.  
Despite these limitations, the study was still able to 
give substantial information about comparative 
benefits of an Ayurvedic treatment plan involving 
multi route drug application in cases of depression 
and suggests about designing a specific treatment 
strategy to treat the individuals on the basis of their 
dominating symptoms and not on the basis of their 
diagnosis alone. This study strongly proposes 
personalized psychiatry25, as the future approach in 
psychiatry. Exploring nasal routes of drug 
applications in psychiatry is also one promising 
research avenue in psychiatry which is opened 
through this study.  
Conclusion 
Continuously rising mental diseases clubbed with 
inadequacies of current approaches to handle them 
across the globe pose a dreadful global challenge. For 
its obvious differences from physical illness in terms 
of etiology, clinical features and impacts, a mental 
disease requires much more to be done in contrast to 
the physical illnesses. Although, the ideal strategy to 
meet the emerging challenges of the mental health is 
to ensure the optimal, accessible and affordable care 
for each one who is in need of it, this seems a near 
impossible task in near future.  
Optimizing the mental health care by duly utilizing 
the traditional and alternative health care systems may 
seem promising approach in India and at other 
places26,27 where a pluralistic health care delivery 
model is officially adopted and where systems like 
Ayurveda and Yoga enjoy a position of repute for 
their ethno cultural contexuatilty. Out of a great 
variety of mental diseases the most prevalent among 
all is depression. India is recently identified as 6th 
country in the world having a huge population 
suffering with depression. Depression is unique in 
sense of its etiology arriving from a faulty 
surrounding including home and work place and is 
also unique for its huge impacts on social and 
personal life accounting it to be a big cause of YLD 
and DALY. Seeing the limitations of conventional 
care of depression, on account of the huge burden of 
the disease and also on account of limitations 
associated with resources and drug therapy, this 
seems appropriate to look at alternative therapies to 
see if these can be of some help to share the burden of 
depression in India.  
A literature search has identified Lasunadya Ghrita 
as one potential drug from Ayurveda recommended 
for the treatment of depression-like symptoms. To 
screen its possible efficacy in treating mild to 
moderate depression, a non random open clinical 
study was done where effects of LG through a multi 
route application were compared with conventional 
modern care consisted of Escitalopram, Atizolam and 
Zolpidam through parameters like HAM-D and SF-
36. A comparable efficacy of Ayurvedic preparation 
in improving the depression symptoms found in the 
study was suggestive of potential of ayurvedic 
therapies in managing depression symptoms and 
hence  suggests more serious exploration in the area 
to effectively utilize the traditional health care 
wisdom of Ayurveda pertinent to India to improve its 




mental health care status in general. This may 
particularly be more relevant to depression for which 
the trial was actually done.  
 
Conflict of interest 
Authors declare that they do not have any conflict 
of interest related to this manuscript. 
 
Authors’ contributions 
SR- Study design and protocol, monitoring and 
analysis; VT- Study execution and analysis; AK- Review 
of the literature, Monitoring and AN- Study design and 
protocol, approval of final manuscript.  
 
References 
1 Vigo D, Thornicroft G & Atun R, Estimating the true global 
burden of mental illness, Lancet Psychiatry, 3 (2) (2016)  
171-178. https://doi.org/10.1007/s11920-019-0997-0 
2 Lake J & Turner M S, Urgent need for improved mental 
health care and a more collaborative model of care, Perm J, 
21 (2017) 17–024. doi:10.7812/TPP/17-024 
3 Srivastava K, Chatterjee K & Bhat P S, Mental health 
awareness: The Indian scenario, Ind Psychiatry J, 25 (2) 
(2016) 131–134. doi:10.4103/ipj.ipj_45_17 
4 Lahariya C, Strengthen mental health services for universal 
health coverage in India, J Postgrad Med, 64 (2018) 7-9. 
5 Rudra S, Kalra A, Kumar A & Joe W, Utilization of 
alternative systems of medicine as health care services in 
India: Evidence on AYUSH care from NSS 2014, PLoS 
ONE, 12 (5) (2017) e0176916. https://doi.org/10.1371 
/journal.pone.0176916 
6 Singh R H & Rastogi S, National Mental Health Care Act 
2017: Possible implications to Ayush, Annals Ayurvedic 
Med, 6 (1-2) (2017) 1-4. 
7 Beck A, Crain A L, Solberg L I, et al., Severity of depression 
and magnitude of productivity loss, Ann Fam Med, 9 (4) 
(2011) 305–311. doi:10.1370/afm.1260 
8 Depression in India: let’s Talk, World Health Organization 
2017, available at http://www.searo.who.int/india/ depression 
_in_india.pdf (Last accessed on 2.8.19) 
9 McLaughlin K A, The public health impact of major 
depression: a call for interdisciplinary prevention efforts, 
Prev Sci, 12 (4) (2011) 361–371. doi:10.1007/s11121-011-
0231-8 
10 Depression and other common mental disorders: Global 
health estimates, Geneva, World Health Organisation; 2017 
(http://apps.who.int/iris/handle/10665/254610/). 
11 GBD 2015 Disease and Injury Incidence and Prevalence 
Collaborators, Global, regional, and national incidence, 
prevalence and years lived with disability for 310 diseases 
and injuries, 1990–2015: a systematic analysis for the global 
burden of disease study 2015, Lancet, 388 (10053) (2016) 
1545-1602. Doi: 10.1016/S0140-6736(16)31678-6 
12 Blackburn T P, Depressive disorders: Treatment failures and 
poor prognosis over the last 50 years, Pharmacol Res 
Perspect, 7 (3) (2019) p.e00472. 
13 Boge K, Zieger A, Mungee A, Tandon A, Fuchs L M, et al., 
Perceived stigmatization and discrimination of people with 
mental illness: A survey-based study of the general 
population in five metropolitan cities in India, Indian J 
Psychiatry, 60 (2018) 24-31. 
14 Krishnamurthy M N & Telles S, Assessing depression 
following two ancient Indian interventions: Effects of Yoga 
and Ayurveda on older adults in a residential home,  
J Gerontol Nurs, 33 (2) (2007) 17-23. 
15 Gautam S, Jain A, Gautam M, Vahia V N & Grover S, 
Clinical practice guidelines for the management of 
depression, Indian J Psychiatry, 59 (Suppl 1) (2017)  
S34–S50. doi:10.4103/0019-5545.196973 
16 Steer E, A cross comparison between Ayurvedic etiology of 
major depressive disorder and bidirectional effect of gut 
dysregulation," J Ayurveda Integr Med, 10 (1) (2019) 59-66. 
17  https://www.icd10data.com/ICD10CM/Codes/F01-F99/F30-
F39/F32-/F32.9 
18 Tripathi B N, Charak Samhita, Chikitsa Sthana 9 Verse 51 
(Lasunadya Ghrita), Chaukhambha Surbharati, Varanasi, 
1983  
19 Hamilton M, A rating scale for depression. J Neurol 
Neurosurg Psychiat, 23 (1960) 56–62. 
20 SF-36 Quality of Life Score, https://clinmedjournals.org/ 
articles/jmdt/jmdt-2-023-figure-1.pdf 
21 Gupta R, Cultural diversity and mental health, Indian J Soc 
Psychiatry, 34 (2018) 4-6. 
22 Raut A A, Mukund S C & Ashok D B V, Reverse 
pharmacology, Reverse pharmacology, In: Innovative 
Approaches in Drug Discovery, by B Patwardhan &  
R Chajuturu (etc.), Elsevier, 2017, P.89-126. 
23 Graff C L & Gary M P, Nasal drug administration: potential 
for targeted central nervous system delivery, J Pharm Sci, 94 
(6) (2005) 1187-1195. 
24 Andrade C, Intranasal drug delivery in neuropsychiatry: 
focus on intranasal ketamine for refractory depression, J Clin 
Psychiatry, 76 (5) (2015) 628-631. 
25 Alda M, Personalized psychiatry: many questions, fewer 
answers, J Psychiatry Neurosci, 38 (6) (2013) 363–365. 
doi:10.1503/jpn.130221 
26 Sasikumar & Latif F, Effect of mindfulness based stress 
reduction (MBSR) on stress, depression and mindfulness 
among Type 2 Diabetics-A randomized pilot study, Indian J 
Tradit Know, 16 (4) ( 2017) 654-659.  
27 Erdogan Z & Cinar S, The effect of Reiki on depression in 
elderly people living in nursing home, Indian J Tradit Know, 
15 (1) (2016) 35-40.  
 
